Can a Two-Pill combo calm the Gut's inflammatory fire?
NCT ID NCT07767370
First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time
Summary
This early-stage trial explores whether adding two experimental capsules, ND-12 and H-6, to standard mesalazine treatment can better control chronic inflammatory diarrhea in adults, including those with active ulcerative colitis. Participants will take the combination or a placebo for 14 days. The study measures changes in a stool marker of gut inflammation (fecal calprotectin) and tracks how many people achieve a meaningful clinical response.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ND-12 and H-6 capsules combined with mesalazine
- What this could lead to
- If it works, this combination could offer a new way to reduce gut inflammation and improve symptoms for people with chronic inflammatory diarrhea.
- What could go wrong
- This is a very early, small trial, so results may not hold up in larger studies. The treatment could also cause side effects or fail to outperform standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 36 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2026
- Expected to finish
-
Aug 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Subjects aged 18-75 years (inclusive), of any gender. 2. Meet any one of the following conditions: 1) Previously diagnosed ulcerative colitis, currently in the active phase; 2) Diagnosis of chronic diarrhoea: stool frequency ≥3 times per day or markedly higher than the subject's usual baseline; disease duration \>4 weeks; recurrent diarrhoea with an interval of 2-4 weeks between episodes; loose stools (Bristol Stool Form Scale type 5, 6, or 7). 3\. Faecal calprotectin \>150 μg/g. 4.The subject or their legal representative provides informed consent by voluntarily signing the informed consent form, fully understands the study objectives, maintains effective communication with investigators, and is capable of understanding and complying with all requirements specified in this study protocol. Exclusion Criteria: Exclusion criteria related to chronic diarrhoea 1. Presence of any of the following symptoms: 1. Fever ≥37.5°C; 2. Moderate-to-severe dehydration requiring intravenous fluid replacement; 3. Recurrent vomiting. 2. Diarrhoea caused by enteric pathogens (e.g., Clostridioides difficile, Salmonella typhi, etc.). 3. Underlying diseases that may trigger diarrhoea, including hyperthyroidism, gastrointestinal autonomic nervous dysfunction, gastrointestinal malignancy, Crohn's disease, history of colectomy (appendectomy, haemorrhoid surgery and fistula-in-ano surgery excluded), history of small-bowel resection (\>20 cm of resected intestinal segment), etc. Drug-related exclusion criteria 4. Suspected drug-induced diarrhoea (e.g., long-term use of laxatives, antibiotics, chemotherapeutic agents, etc.) where discontinuation of the offending drug is not feasible. 5. History of allergy to any component of mesalazine capsules, ND-12 capsules or H-6 capsules. 6. Anticipated need for prohibited medications during the study (e.g. antibiotics, antidiarrhoeals, antiemetics, antispasmodics, etc.). 7. Use of any investigational drug within 30 days prior to enrolment into this study. Other gastrointestinal exclusion criteria 8. History of gastrectomy or vagotomy. 9. Known malabsorptive disorders include coeliac disease. 10. Known lactose intolerance. 11. Any suspected condition requiring abdominal surgery. Other exclusion criteria 12. Confirmed human immunodeficiency virus (HIV) positive status, known or suspected immunosuppression. 13. Known severe hepatic or renal insufficiency. 14. Past or current history of alcohol abuse and/or known substance abuse (cocaine, heroin, cannabis, etc.). 15. Any psychiatric condition impairing the subject's ability to understand the nature, scope and potential consequences of the study, and/or documented evidence of non-cooperation. 16. Pregnant or lactating women.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diarrhea chronic are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210011, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug D-2570 aims to quiet Flare-Ups in ulcerative colitis
- Gut check: 4,000-Person study links diet, genes, and stomach troubles
- New drug LYNC-101 enters first human trials for ulcerative colitis
- New oral drug could replace steroids for severe colitis Flare-Ups
- Village health workers cut deaths in remote indian tribes
- New hope for ulcerative colitis: experimental drug OD-07656 enters Mid-Stage trial